Eovist

Eovist is a brand name of gadoxetate disodium, approved by the FDA in the following formulation(s):

EOVIST (gadoxetate disodium - solution; intravenous)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: July 3, 2008
  
  Strength(s): 1.8143GM/10ML (181.43MG/ML) ^[RLD]

Has a generic version of Eovist been approved?

No. There is currently no therapeutically equivalent version of Eovist available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eovist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Eovist.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 3, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Eovist Consumer Information (Drugs.com)
• Eovist Consumer Information (Cerner Multum)
• Eovist Advanced Consumer Information (Micromedex)
• Gadoxetate Consumer Information (Cerner Multum)
• Gadoxetate Intravenous Advanced Consumer Information (Micromedex)